Related Experiment Video
Updated: Jul 11, 2025

Transcranial Direct Current Stimulation for Online Gamers
Published on: November 9, 2019
Relapse prevention therapy for internet gaming disorder in Swedish child and adolescent psychiatric clinics: a
Frida André1, Sabina Kapetanovic2, Isak Einarsson1,3
1Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University, Lund, Sweden.
Objectives:
To evaluate the effectiveness of relapse prevention (RP) as a treatment for internet gaming disorder (IGD).
Design:
Randomized controlled trial.
Setting:
Three child and adolescent psychiatry (CAP) units in Region Skåne, Sweden.
Participants:
Children aged 13-18 years, coming for their first visit to CAP during 2022, were screened for gaming behavior. Those who met the proposed DSM-5 criteria for IGD were offered participation in the trial, if they had the capacity to provide written informed consent and if they spoke Swedish. A total of 111 CAP patients agreed to participate. Out of those, 11 patients were excluded due to incorrect inclusion such as young age (n = 1), or due to the absence of responses to follow-up measures (n = 9). After exclusion, 102 participants remained (intervention = 47, control = 55).
Interventions:
The intervention, RP, is based on cognitive behavioral treatment (CBT) and was provided individually, comprising of five to seven 45-min sessions over a period of 5 to 7 weeks versus treatment as usual.
Outcome Measures:
Participants were assessed with Game Addiction Scale for Adolescents pre-treatment (GASA) (baseline), post-treatment (treatment group only), and 3 months after baseline (follow-up).
Results:
The repeated measures ANOVA showed a significant interaction effect between treatment and time. Both the control group and treatment group lowered their mean GASA score from baseline to follow-up significantly, but the improvement was greater in the treatment group (mean difference in control group -5.1, p < 0.001, 95% CI = - 3.390 to -6.755, mean difference in treatment group -9.9, p < 0.001, 95% CI = -11.746 to -8.105).
Conclusion:
RP was found to be superior to treatment as usual in terms of reduction of IGD symptoms. Future research should address which aspects within a given treatment are effective, who benefits from treatment, in what aspects, and why.
Trial Registration Number:
ClinicalTrials.gov, NCT05506384 https://clinicaltrials.gov/ct2/show/NCT05506384.

